Skip to main content
OpenTrials
Recruiting

NCT Number: NCT06507930

The COMPASSION Study

The aim of this research study is to better understand the in-home hospice experience for participants, caregivers, hospice nurses, and oncology providers by conducting telehealth check-ins between participants and caregivers and oncology care teams.

Recruiting

Interested in participating?

Request Info

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Dana-Farber Cancer Institute

Boston, Massachusetts, 02215, United States

Location status: Recruiting

Location contact

Claire Smith, MD

CONTACT

[email protected]

617-632-3800

Claire Smith, MD

PRINCIPAL_INVESTIGATOR

About this study

The aim of this research study is to better understand the in-home hospice experience for participants, caregivers, hospice nurses, and oncology providers by conducting telehealth check-ins between participants and caregivers and oncology care teams.

Study procedures include giving verbal consent to participate and a one-time survey delivered by email or phone call.

About 200 people, which includes 50 participants, 50 caregivers, 50 hospice nurses, and about 50 oncology providers, are expected to participate in this research study.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patient of any gender with unresectable locally advanced or metastatic breast cancer
  • Eligible for in-home hospice services and referred by DFCI clinical team to in-home hospice </= 1 week before enrollment
  • Ability to conduct video or phone check-ins, even if assistance required.
  • Able to provide verbal consent with a willingness to take a survey at 4-6 weeks, if medically able
  • Hospice setting is within Massachusetts
  • Non-English language allowed but interpreter services must be present at each meeting and will be coordinated by scheduling team
  • Willingness to provide a caregiver/loved one's contact information for survey contact at 4 weeks after enrollment

Exclusion criteria

  • Unable to provide verbal consent
  • Hospice care planned outside of a home setting (note: if participants start out in a home hospice setting but later transition their hospice care to an inpatient setting, enrollment is allowed as long as they started in a home setting)
  • Hospice setting outside of Massachusetts
  • Individuals who are under the age of 18, as this is not a project focused on pediatric patients.

Treatment and study plan

Telehealth Hospice Visits

Other

Telehealth check-in appointments with oncology care team, MD, PA, NP, or hospice nurse, via HIPAA compliant telehealth platform, Zoom, or by phone call.

Primary outcomes

  1. Proportion of Participant Intervention Completion

    Time frame: Up to 4 weeks

    Feasibility of the telehealth intervention is defined as greater than or equal to 80% of enrolled participants (18 out of 25) completing greater than or equal to 66% of the planned telehealth check-ins while the participant remains alive.

Study contacts

Contact information is provided by the study sponsor or research team.

Claire Smith, MD

CONTACT

[email protected]

617-632-3800

Sponsors and collaborators

Lead sponsor

Dana-Farber Cancer Institute

Other

Registry information

Official study title

The COMPASSION Study: Applying Telehealth to Innovate and Strengthen Connections for Patients With Metastatic Breast Cancer Receiving Hospice Care

Important dates

Study start
2024
Primary completion
2026
Study completion
2027
First posted
Jul 18, 2024
Registry last updated
Oct 9, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.